Whoop, the Boston-based fitness wearable and health subscription company, closed a $575 million Series G funding round at a $10.1 billion valuation, the company announced, in a deal that crystallises one of the sharpest private-market repricing stories in consumer health technology.
The figure is a significant step up. Whoop's valuation stood at $3.6 billion less than five years ago, meaning the latest round represents nearly a threefold increase in assessed worth over that period. The Series G round drew a notably broad investor base: Abbott Laboratories, the Illinois-based diagnostics and medical devices conglomerate, joined as a strategic backer, alongside sovereign wealth funds and major healthcare institutions. Athletes LeBron James and Cristiano Ronaldo also participated.
The financial case for that valuation rests on a set of 2025 operating metrics that the company disclosed alongside the raise. Whoop reported 103% year-over-year subscription growth and said it more than doubled revenue during the year, while also reaching cash flow positivity, a threshold that carries weight with institutional investors evaluating an IPO-ready candidate.
Whoop IPO Timeline and 75% Workforce Expansion Plan
The funding round is widely read as pre-IPO positioning. Whoop is reportedly preparing for an initial public offering, though no filing date has been confirmed publicly. The company's hiring strategy adds texture to that read: Whoop plans to expand its workforce by 75% ahead of any public listing, a scale of staffing investment that typically precedes the operational and compliance demands of going public. Pre-IPO headcount expansions of that magnitude are generally driven by the need to build out finance, legal, and regulatory infrastructure that public market scrutiny requires.
Beyond the IPO mechanics, Whoop is making a broader platform argument to investors. The company describes itself as building a comprehensive health operating system, using artificial intelligence to predict medical conditions before symptoms present. The company's wearable device, a screenless fitness tracker worn on the wrist that monitors heart rate variability, sleep, and recovery, currently operates on a subscription model rather than a one-time hardware purchase, which accounts for the recurring revenue base underpinning its bookings growth figures. Abbott Laboratories' participation as a strategic investor signals an intent to move closer to clinical-grade health monitoring, a market segment that carries higher regulatory scrutiny but also substantially larger addressable revenue than consumer wellness alone.
The $10.1 billion valuation places Whoop in a competitive tier alongside established consumer health platforms, though the company remains privately held and its financials have not been subject to the disclosure requirements that govern public companies. The planned 75% workforce increase, combined with the Series G capital and the stated IPO preparation, frames the current moment as a deliberate inflection point rather than a routine funding event.
